Skip to main content
Top
Published in: Acta Neuropathologica 2/2010

01-08-2010 | Original Paper

Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes

Authors: Marcel Seiz, Jochen Tuettenberg, Jochen Meyer, Marco Essig, Kirsten Schmieder, Christian Mawrin, Andreas von Deimling, Christian Hartmann

Published in: Acta Neuropathologica | Issue 2/2010

Login to get access

Abstract

The current WHO classification of brain tumors defines gliomatosis cerebri (GC) as an extensively infiltrating astrocytic glioma involving at least three cerebral lobes. The relation of GC to diffuse astrocytomas and glioblastoma is uncertain. Due to malignant biological behavior, GC is allotted to WHO grade III. Recent reports showed IDH1 mutations in astrocytic and oligodendroglial tumors WHO grades II and III and in secondary glioblastomas with a frequency of up to 90%, whereas IDH1 mutations occurred in only 5% of primary glioblastomas. Here, we examined the frequency of IDH1 mutations in 35 GC samples by direct sequencing, derived cleaved amplified polymorphic sequence analysis and immunohistochemistry. We identified IDH1 mutations in 10/24 (42%) cases, which also included a solid tumor portion (type 2 GC), but not in 11 “classical” cases without solid tumor mass (type 1 GC). TP53 mutations were revealed in two type 2 GC, but not in any type 1 GC, while combined chromosomal losses of 1p and 19q were not found at all. Our data suggest that GC consists of two histological/molecular subtypes, type 1 being clearly distinct from diffuse astrocytoma, and type 2 sharing features with diffuse astrocytoma.
Literature
1.
go back to reference Balss J, Meyer J, Mueller W et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597–602CrossRefPubMed Balss J, Meyer J, Mueller W et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597–602CrossRefPubMed
2.
go back to reference Bleeker FE, Atai NA, Lamba S et al (2010) The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 119:487–494CrossRefPubMed Bleeker FE, Atai NA, Lamba S et al (2010) The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 119:487–494CrossRefPubMed
3.
go back to reference Capper D, Weissert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254CrossRefPubMed Capper D, Weissert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254CrossRefPubMed
4.
go back to reference Capper D, Zentgraf H, Balss J et al (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599–601CrossRefPubMed Capper D, Zentgraf H, Balss J et al (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599–601CrossRefPubMed
5.
go back to reference Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744CrossRefPubMed Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744CrossRefPubMed
6.
go back to reference Dubbink HJ, Taal W, van Marion R et al (2009) IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73:1792–1795CrossRefPubMed Dubbink HJ, Taal W, van Marion R et al (2009) IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73:1792–1795CrossRefPubMed
7.
go back to reference Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 118:469–474CrossRefPubMed Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 118:469–474CrossRefPubMed
8.
go back to reference Herrlinger U, Felsberg J, Kuker W et al (2002) Gliomatosis cerebri: molecular pathology and clinical course. Ann Neurol 52:390–399CrossRefPubMed Herrlinger U, Felsberg J, Kuker W et al (2002) Gliomatosis cerebri: molecular pathology and clinical course. Ann Neurol 52:390–399CrossRefPubMed
9.
go back to reference Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341–347CrossRefPubMed Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341–347CrossRefPubMed
10.
go back to reference Jennings MT, Frenchman M, Shehab T et al (1995) Gliomatosis cerebri presenting as intractable epilepsy during early childhood. J Child Neurol 10:37–45CrossRefPubMed Jennings MT, Frenchman M, Shehab T et al (1995) Gliomatosis cerebri presenting as intractable epilepsy during early childhood. J Child Neurol 10:37–45CrossRefPubMed
11.
go back to reference Kannuki S, Hondo H, Ii K et al (1997) Gliomatosis cerebri with good prognosis. Brain Tumor Pathol 14:53–57CrossRefPubMed Kannuki S, Hondo H, Ii K et al (1997) Gliomatosis cerebri with good prognosis. Brain Tumor Pathol 14:53–57CrossRefPubMed
12.
go back to reference Kleihues P, Burger PC, Scheithauer BW et al (1993) Histological typing of tumours of the central nervous system, 2nd edn. Springer, Berlin Kleihues P, Burger PC, Scheithauer BW et al (1993) Histological typing of tumours of the central nervous system, 2nd edn. Springer, Berlin
13.
go back to reference Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system, 2nd edn. IARC Press, Lyon Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system, 2nd edn. IARC Press, Lyon
14.
go back to reference Kros JM, Zheng P, Dinjens WN et al (2002) Genetic aberrations in gliomatosis cerebri support monoclonal tumorigenesis. J Neuropathol Exp Neurol 61:806–814PubMed Kros JM, Zheng P, Dinjens WN et al (2002) Genetic aberrations in gliomatosis cerebri support monoclonal tumorigenesis. J Neuropathol Exp Neurol 61:806–814PubMed
15.
go back to reference Louis DN, International Agency for Research on Cancer (2007) WHO classification of tumours of the central nervous system. World Health Organization classification of tumours, 4th edn. International Agency for Research on Cancer, Lyon Louis DN, International Agency for Research on Cancer (2007) WHO classification of tumours of the central nervous system. World Health Organization classification of tumours, 4th edn. International Agency for Research on Cancer, Lyon
16.
go back to reference Mawrin C (2005) Molecular genetic alterations in gliomatosis cerebri: what can we learn about the origin and course of the disease? Acta Neuropathol 110:527–536CrossRefPubMed Mawrin C (2005) Molecular genetic alterations in gliomatosis cerebri: what can we learn about the origin and course of the disease? Acta Neuropathol 110:527–536CrossRefPubMed
17.
go back to reference Mawrin C, Aumann V, Kirches E et al (2001) Gliomatosis cerebri: post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide. J Neurooncol 55:11–17CrossRefPubMed Mawrin C, Aumann V, Kirches E et al (2001) Gliomatosis cerebri: post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide. J Neurooncol 55:11–17CrossRefPubMed
18.
go back to reference Mawrin C, Kirches E, Schneider-Stock R et al (2003) Analysis of TP53 and PTEN in gliomatosis cerebri. Acta Neuropathol 105:529–536PubMed Mawrin C, Kirches E, Schneider-Stock R et al (2003) Analysis of TP53 and PTEN in gliomatosis cerebri. Acta Neuropathol 105:529–536PubMed
19.
go back to reference Mawrin C, Lins H, Kirches E et al (2003) Distribution of p53 alterations in a case of gliomatosis cerebri. Hum Pathol 34:102–106CrossRefPubMed Mawrin C, Lins H, Kirches E et al (2003) Distribution of p53 alterations in a case of gliomatosis cerebri. Hum Pathol 34:102–106CrossRefPubMed
20.
go back to reference Meyer J, Pusch S, Balss J et al (2010) PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol 20:298–300CrossRefPubMed Meyer J, Pusch S, Balss J et al (2010) PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol 20:298–300CrossRefPubMed
22.
go back to reference Park S, Suh YL, Nam DH et al (2009) Gliomatosis cerebri: clinicopathologic study of 33 cases and comparison of mass forming and diffuse types. Clin Neuropathol 28:73–82PubMed Park S, Suh YL, Nam DH et al (2009) Gliomatosis cerebri: clinicopathologic study of 33 cases and comparison of mass forming and diffuse types. Clin Neuropathol 28:73–82PubMed
23.
go back to reference Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812CrossRefPubMed Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812CrossRefPubMed
24.
go back to reference Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154CrossRefPubMed Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154CrossRefPubMed
25.
go back to reference Taillibert S, Chodkiewicz C, Laigle-Donadey F et al (2006) Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. J Neurooncol 76:201–205CrossRefPubMed Taillibert S, Chodkiewicz C, Laigle-Donadey F et al (2006) Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. J Neurooncol 76:201–205CrossRefPubMed
26.
go back to reference Ware ML, Hirose Y, Scheithauer BW et al (2007) Genetic aberrations in gliomatosis cerebri. Neurosurgery 60:150–158 (discussion 158)CrossRefPubMed Ware ML, Hirose Y, Scheithauer BW et al (2007) Genetic aberrations in gliomatosis cerebri. Neurosurgery 60:150–158 (discussion 158)CrossRefPubMed
27.
go back to reference Watanabe T, Nobusawa S, Kleihues P et al (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:653–656 Watanabe T, Nobusawa S, Kleihues P et al (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:653–656
28.
go back to reference Weller M, Felsberg J, Hartmann C et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the german glioma network. J Clin Oncol 27:5743–5750CrossRefPubMed Weller M, Felsberg J, Hartmann C et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the german glioma network. J Clin Oncol 27:5743–5750CrossRefPubMed
29.
go back to reference Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880CrossRefPubMed Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880CrossRefPubMed
30.
go back to reference Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRefPubMed Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRefPubMed
31.
go back to reference Zhao S, Lin Y, Xu W et al (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324:261–265CrossRefPubMed Zhao S, Lin Y, Xu W et al (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324:261–265CrossRefPubMed
32.
go back to reference Zülch KJ, World Health Organization (1979) Histological typing of tumours of the central nervous system. World Health Organization, Geneva Zülch KJ, World Health Organization (1979) Histological typing of tumours of the central nervous system. World Health Organization, Geneva
Metadata
Title
Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes
Authors
Marcel Seiz
Jochen Tuettenberg
Jochen Meyer
Marco Essig
Kirsten Schmieder
Christian Mawrin
Andreas von Deimling
Christian Hartmann
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Acta Neuropathologica / Issue 2/2010
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-010-0701-2

Other articles of this Issue 2/2010

Acta Neuropathologica 2/2010 Go to the issue